Sucampo Reports Third Quarter 2016 Financial Results
November 09, 2016 06:30 ET
|
Sucampo Pharmaceuticals Inc
Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr....
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
June 15, 2015 16:02 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
May 15, 2015 16:02 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
Sucampo and Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement for AMITIZA(R) (lubiprostone) in China
May 11, 2015 16:02 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that it entered into an exclusive license,...
Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Earnings Call
February 18, 2015 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...
AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
January 30, 2015 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the successful completion of the European...
Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada
December 30, 2014 17:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Health Canada has accepted the...
Sucampo Announces Third Quarter 2014 Financial Results
November 06, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
Strong Revenue and Sales Growth for AMITIZA
Raises 2014 Earnings Guidance, Excluding Special Items
CEO Peter Greenleaf to Provide Update on Significant Progress Against Strategic Plan...
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
October 21, 2014 18:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda...
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
October 14, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an...